Studies have shown that active fund managers routinely underperform the S&P500 index*​

Corcept Therapeutics Incorporated (NASDAQ: CORT)

CORT Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
165.70%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
25.60%

CORT Stock Analysis

CORT PE Ratio: 207.6

CORT PEG Ratio: 0.8

CORT Forward EPS Growth (12 month): 264.30%

CORT PS Ratio: 10.1

CORT PSG Ratio: 0.3

CORT Forward Revenue Growth (12 month): 31.20%

CORT Articles

No data was found